Immunotherapy

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.

What is Immunotherapy?

Immunotherapy is a treatment that is designed to harness the ability of the body’s immune system to combat infection or disease.

Activation Immunotherapies

Immunotherapy and Helminthic Therapy

Suppression Immunotherapies

Immunotherapy: Past, Present and Future

Adoptive T Cell Therapy Methodology

Adoptive T Cell Therapy Applications

Immunotherapy: The Future of Lung Cancer Treatment?

Neoantigens' Role in Immunotherapy

Latest Immunotherapy News and Research

Adding SBRT to sorafenib improves survival in hepatocellular carcinoma patients

Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved progression-free survival (PFS) and time-to-progression in patients with locally advanced hepatocellular carcinoma (HCC) when compared to sorafenib alone.

20 Dec 2024

Breakthrough in antigen recognition: TRACeR-I enhances immune targeting

Researchers describe TRACeR-I, a protein platform that can be used to engineer immune responses.

19 Dec 2024

Scientists discover key protein that helps cancer cells evade CAR T cell therapy

Scientists at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, have collared a tricky culprit that helps cancer cells evade CAR T cell therapy.

17 Dec 2024

Chemical compound lights up treatment-resistant cancers on imaging scans

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical professionals better target and treat cancer.

17 Dec 2024

WashU Medicine receives $10.8 million grant to advance blood cancer research

Continuing its role as a leader in leukemia research, Washington University School of Medicine in St. Louis has been awarded a five-year, $10.8 million grant to further its exceptional programs in leukemia and other blood cancers.

16 Dec 2024

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

Australian research unlocks new path for cancer immunotherapy

Australian-led research is unlocking new ways for immunotherapy to better target cancer.

14 Dec 2024

Promising combination therapy could improve liver cancer outcomes

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in Cancer Immunology Research, "Combination CXCR4 and PD1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma."

14 Dec 2024

Cardio-oncology experts highlight importance of heart health in cancer care

The devastating news of a cancer diagnosis understandably makes doctors and patients focus on the cancer itself.

13 Dec 2024

Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancer

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and potential therapeutic strategies.

13 Dec 2024

New protein platform enhances cancer immunotherapy

Researchers from Children's Hospital of Philadelphia (CHOP) and Stanford University have revealed the molecular structure of TRACeR-I, a protein platform for reprogramming immune responses. A better understanding of its structure may help optimize designs for the platform, which can be used to develop cancer treatments by either directly modifying immune cells or by creating proteins that help immune cells locate cancer cells. The findings were published today by the journal Nature Biotechnology.

13 Dec 2024

PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung cancer.

11 Dec 2024

Study pinpoints how a network of different proteins controls rest and activation

Cells in the immune system don't always fight; they often rest and wait for threats, like viruses or bacteria.

11 Dec 2024

Understanding how angiogenesis contributes to drug resistance in breast cancer

Breast cancer, the most common cancer among women, is notorious for its ability to develop resistance to a wide range of treatments, including surgery, chemotherapy, targeted therapies, and immunotherapy.

11 Dec 2024

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

11 Dec 2024

Prostate cancer vaccines: Progress, challenges, and future directions

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in clinical effectiveness and validation.

11 Dec 2024

High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following their initial treatment.

11 Dec 2024

New $1.4M grant supports innovative kidney cancer treatment strategy

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

10 Dec 2024

First-in-class monoclonal antibody shows promise for rare, aggressive hyperinflammatory condition

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Dec 2024

Lab-grown tumor organoids predict patient response to CAR T cell therapy

For the first time, researchers used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to accurately model a patient's response to CAR T cell therapy in real time.

9 Dec 2024